| __timestamp | Gilead Sciences, Inc. | Pharming Group N.V. |
|---|---|---|
| Wednesday, January 1, 2014 | 2983000000 | 4042025 |
| Thursday, January 1, 2015 | 3426000000 | 5279557 |
| Friday, January 1, 2016 | 3398000000 | 8073913 |
| Sunday, January 1, 2017 | 3878000000 | 44864073 |
| Monday, January 1, 2018 | 4056000000 | 53488904 |
| Tuesday, January 1, 2019 | 4381000000 | 65896361 |
| Wednesday, January 1, 2020 | 5151000000 | 69968267 |
| Friday, January 1, 2021 | 5246000000 | 92047281 |
| Saturday, January 1, 2022 | 5673000000 | 131819000 |
| Sunday, January 1, 2023 | 6090000000 | 87501000 |
| Monday, January 1, 2024 | 6091000000 |
Unleashing the power of data
In the competitive world of pharmaceuticals, managing Selling, General, and Administrative (SG&A) expenses is crucial for profitability. Gilead Sciences, Inc. and Pharming Group N.V. offer a fascinating study in contrasts over the past decade. From 2014 to 2023, Gilead's SG&A expenses have surged by over 100%, peaking at $6.09 billion in 2023. In contrast, Pharming Group's expenses, though significantly lower, have increased by more than 2,000%, reaching approximately $87.5 million in the same year.
While Gilead's larger scale allows for higher absolute expenses, Pharming's rapid growth in SG&A costs reflects its aggressive expansion strategy. This data highlights the different paths these companies have taken in optimizing their operational costs. As the pharmaceutical landscape evolves, the ability to manage these expenses effectively will be a key determinant of future success.
SG&A Efficiency Analysis: Comparing AstraZeneca PLC and Pharming Group N.V.
Who Optimizes SG&A Costs Better? Pfizer Inc. or Pharming Group N.V.
Selling, General, and Administrative Costs: Gilead Sciences, Inc. vs Neurocrine Biosciences, Inc.
Who Optimizes SG&A Costs Better? Gilead Sciences, Inc. or Intra-Cellular Therapies, Inc.
Breaking Down SG&A Expenses: Gilead Sciences, Inc. vs Axsome Therapeutics, Inc.
Cost Management Insights: SG&A Expenses for Gilead Sciences, Inc. and Opthea Limited
Selling, General, and Administrative Costs: Gilead Sciences, Inc. vs Xenon Pharmaceuticals Inc.
Who Optimizes SG&A Costs Better? BioMarin Pharmaceutical Inc. or Pharming Group N.V.
Operational Costs Compared: SG&A Analysis of Pharming Group N.V. and Axsome Therapeutics, Inc.
Cost Management Insights: SG&A Expenses for Pharming Group N.V. and Opthea Limited
Breaking Down SG&A Expenses: Pharming Group N.V. vs ACADIA Pharmaceuticals Inc.
Who Optimizes SG&A Costs Better? Pharming Group N.V. or Agios Pharmaceuticals, Inc.